MALVERN, Pa., Nov. 18, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) ("Endo") announced today that one of its operating subsidiaries, Endo USA, Inc., is expanding its previously announced voluntary ...
(RTTNews) - Viatris (VTRS) announced the launch in Canada of Gen-Clozapine orally disintegrating tablets, providing a new treatment option for treatment-resistant schizophrenia patients. This marks ...
SOMERSET, N.J., Mar. 7, 2019 /PRNewswire-PRWeb/ -- Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer ...
Endo, Inc (OTCQX: NDOI) (“Endo”), announced today that one of its operating subsidiaries, Endo USA, Inc., is voluntarily recalling one lot of Clonazepam Orally Disintegrating Tablets, USP (C-IV) 0.25 ...
Zacks Investment Research on MSN
MNMD stock up more than 100% in 6 months: What's in store for 2026?
MNMD is developing its lead pipeline candidate MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized form of lysergide D-tartrate, for the treatment of generalized anxiety ...
Please provide your email address to receive an email when new articles are posted on . MindMed will use Catalent’s Zydis orally disintegrating tablet technology for the development of MM-120, an ...
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback